XML 97 R81.htm IDEA: XBRL DOCUMENT v3.22.1
Note 14 - Segment Data - Operating Segment Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Revenues     $ 184,335,000 $ 133,937,000 $ 117,687,000
Revenue     184,335,000 133,937,000 117,687,000
Gross profit (loss)     109,090,000 87,014,000 65,362,000
Operating expenses     104,388,000 74,656,000 57,439,000
Operating income     4,702,000 12,358,000 7,923,000
Nonoperating expense     (1,128,000) (10,055,000) (4,061,000)
Total earnings before income taxes     3,574,000 2,303,000 3,862,000
Depreciation and amortization $ 24,606,000 $ 11,178,000 25,068,000 17,660,000 12,990,000
Depreciation and amortization 24,606,000 11,178,000 25,068,000 17,660,000 12,990,000
Operating Segments [Member]          
Revenues     184,335 133,937 115,224
Revenue     184,335 133,937 115,224
Gross profit (loss)     109,255,000 87,017,000 64,944,000
Operating expenses     104,388,000 74,656,000 57,439,000
Operating income     4,702,000 12,358,000 7,923,000
Nonoperating expense     1,128,000 10,055,000 4,061,000
Operating Segments [Member] | Sterilization and Disinfection Control [Member]          
Revenues [1]     59,044,000 53,119,000 49,660,000
Revenue [1]     59,044,000 53,119,000 49,660,000
Gross profit (loss)     43,720,000 39,870,000 35,797,000
Depreciation and amortization 2,176,000 2,333,000      
Depreciation and amortization 2,176,000 2,333,000      
Operating Segments [Member] | Biopharmaceutical Development [Member]          
Revenues [1]     45,579,000 33,892,000 13,851,000 [2]
Revenue [1]     45,579,000 33,892,000 13,851,000 [2]
Gross profit (loss)     28,605,000 21,035,000 382,000
Depreciation and amortization 4,495,000 4,162,000      
Depreciation and amortization 4,495,000 4,162,000      
Operating Segments [Member] | Calibration Solutions [Member]          
Revenues [1]     46,872,000 46,926,000 51,713,000
Revenue [1]     46,872,000 46,926,000 51,713,000
Gross profit (loss)     24,989,000 26,112,000 28,765,000
Depreciation and amortization 6,133,000 4,683,000      
Depreciation and amortization 6,133,000 4,683,000      
Operating Segments [Member] | Clinical Genomics [Member]          
Revenues [1]     32,840,000 [3] 0 0
Revenue [1]     32,840,000 [3] 0 0
Gross profit (loss)     11,941,000 0 0
Depreciation and amortization 11,802,000 0      
Depreciation and amortization 11,802,000 0      
Corporate, Non-Segment [Member]          
Revenues [1],[4]     0 0 2,463,000
Revenue [1],[4]     0 0 2,463,000
Gross profit (loss) [4]     $ (165,000) $ (3,000) $ 418,000
Depreciation and amortization [5] 0 0      
Depreciation and amortization [5] $ 0 $ 0      
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Biopharmaceutical Development division represent transactions subsequent to the acquisition of Gyros Protein Technologies Holding AB on October 31, 2019.
[3] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.
[4] Non-reportable operating segments (including our Cold Chain Packaging Division which ceased operations during the year ended March 31, 2020) and unallocated corporate expenses are reported within Corporate and Other.
[5] Amortization of intellectual property is included in the calculation of gross margin by segment. Amortization pertaining to other types of intangible assets, such as customer relationships and trademarks, is included in general and administrative on the Consolidated Statements of Income. Within the table above, the depreciation and amortization costs that are included in calculating the gross margin of the noted segment are included; other costs such as amortization that is recorded to general and administrative expense is shown in corporate and other.